Share the post "GlaxoSmithkline Pharmaceuticals : Q4 2024 Financial Quarterly Report : YoY Sales Up 18.08 %, QoQ Up 15.47 %"
Highlights
- Sales over the Year and quarter: The company experienced a substantial growth of 18.08 % in the past year, substantial increase in net sales/revenue by 15.47 %.
- Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 7.85 %. Marginal increase in other income during this quarter, up by 6.12%.
- Profit over the Year and quarter: Significant improvement in profitability for GlaxoSmithkline Pharmaceuticals Ltd.. Notable increase of 45.75 % in net profit Year to Year, GlaxoSmithkline Pharmaceuticals Ltd.’s profitability increased by 325.37 % in this quarter.
- EPS over the Year and quarter: EPS increased by 45.69 % Year to Year. EPS increased by 16.08 % in previous quarter. Positive impact on shareholders.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 787.45 Cr | Rs. 805.26 Cr | Rs. 929.8 Cr | + 15.47 % | + 18.08 % |
| Expenses | Rs. 617.71 Cr | Rs. 587.2 Cr | Rs. 672.54 Cr | + 14.53 % | + 8.88 % |
| Operating Profit | Rs. 169.74 Cr | Rs. 218.06 Cr | Rs. 257.26 Cr | + 17.98 % | + 51.56 % |
| OPM % | 21.56 % | 27.08 % | 27.67 % | + 0.59 % | + 6.11 % |
| Other Income | Rs. 27.66 Cr | Rs. 28.11 Cr | Rs. 29.83 Cr | + 6.12 % | + 7.85 % |
| Interest | Rs. 0.65 Cr | Rs. 0.32 Cr | Rs. 0.77 Cr | + 140.63 % | + 18.46 % |
| Depreciation | Rs. 17.18 Cr | Rs. 17.11 Cr | Rs. 18.1 Cr | + 5.79 % | + 5.36 % |
| Profit before tax | Rs. 179.57 Cr | Rs. 228.74 Cr | Rs. 268.22 Cr | + 17.26 % | + 49.37 % |
| Tax % | 29.76 % | 30.12 % | 28.14 % | -1.98 % | -1.62 % |
| Net Profit | Rs. 133.43 Cr | Rs. 45.72 Cr | Rs. 194.48 Cr | + 325.37 % | + 45.75 % |
| EPS in Rs | Rs. 7.88 | Rs. 9.89 | Rs. 11.48 | + 16.08 % | + 45.69 % |
Today, we’re looking at GlaxoSmithkline Pharmaceuticals Ltd.’s financial performance for the Q4(Mar 2024).Starting with the top line, the company reported a robust year-over-year sales growth of 18.08 %. However, it did see a marginal increase of 15.47 % from the previous quarter. Expenses ticked up slightly by 14.53 % quarter-on-quarter, aligning with the annual rise of 8.88 %. Operating profit, while up 51.56 % compared to last year, faced a quarter-on-quarter increase of 17.98 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 6.11 %, but an expansion of 0.59 % sequentially. Other income rose by 6.12 % compared to the last quarter, despite an annual growth of 7.85 %. Interest expenses surged remarkably by 140.63 % from the previous quarter, yet the year-over-year increase remains at a moderate 18.46 %. Depreciation costs climbed by 5.79 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 5.36 %. Profit before tax grew annually by 49.37 % but saw an increase from the preceding quarter by 17.26 %.
Tax expenses as a percentage of profits decreased slightly by -1.62 % compared to last year, with a more notable quarter-on-quarter decrease of -1.98 %. Net profit rose by 45.75 % year-on-year but experienced a 325.37 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 45.69 % but a quarterly rise of 16.08 %. In summary, GlaxoSmithkline Pharmaceuticals Ltd.’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 787.45 Cr | Rs. 805.26 Cr | Rs. 929.8 Cr | + 15.47 % | + 18.08 % |
| Expenses | Rs. 617.71 Cr | Rs. 587.2 Cr | Rs. 672.54 Cr | + 14.53 % | + 8.88 % |
| Operating Profit | Rs. 169.74 Cr | Rs. 218.06 Cr | Rs. 257.26 Cr | + 17.98 % | + 51.56 % |
| Net Profit | Rs. 133.43 Cr | Rs. 45.72 Cr | Rs. 194.48 Cr | + 325.37 % | + 45.75 % |
| EPS in Rs | Rs. 7.88 | Rs. 9.89 | Rs. 11.48 | + 16.08 % | + 45.69 % |
In reviewing GlaxoSmithkline Pharmaceuticals Ltd.’s 2024(Q4) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 18.08 % year-on-year growth, however, there was a minor increase of 15.47 % from the previous quarter. Expenses rose by 8.88 % compared to the previous year, with a 14.53 % increase quarter-on-quarter. Operating Profit surged by 51.56 % annually, and saw a 17.98 % increase from the last quarter.
Net Profit showed yearly increase of 45.75 %, and experienced a 325.37 % increase from the previous quarter. Earnings Per Share (EPS) rose by 45.69 % annually, however rose by 16.08 % compared to the last quarter. In essence, while GlaxoSmithkline Pharmaceuticals Ltd. exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.
